Cargando…

Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients

As a mental disease in modern society, depression shows an increasing occurrence, with low cure rate and high recurrence rate. It has become the most disabling disease in the world. At present, the treatment of depression is mainly based on drug therapy combined with psychological therapy, physical...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Zhiyu, Han, Yu, Zhang, Danshen, Li, Zhongqiu, Jing, Yongshuai, Hu, Beibei, Sun, Shiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611373/
https://www.ncbi.nlm.nih.gov/pubmed/36297505
http://dx.doi.org/10.3390/pharmaceutics14102070
_version_ 1784819509878587392
author Jin, Zhiyu
Han, Yu
Zhang, Danshen
Li, Zhongqiu
Jing, Yongshuai
Hu, Beibei
Sun, Shiguo
author_facet Jin, Zhiyu
Han, Yu
Zhang, Danshen
Li, Zhongqiu
Jing, Yongshuai
Hu, Beibei
Sun, Shiguo
author_sort Jin, Zhiyu
collection PubMed
description As a mental disease in modern society, depression shows an increasing occurrence, with low cure rate and high recurrence rate. It has become the most disabling disease in the world. At present, the treatment of depression is mainly based on drug therapy combined with psychological therapy, physical therapy, and other adjuvant therapy methods. Antidepressants are primarily administered peripherally (oral and intravenous) and have a slow onset of action. Antidepressant active ingredients, such as neuropeptides, natural active ingredients, and some chemical agents, are limited by factors such as the blood–brain barrier (BBB), first-pass metabolism, and extensive adverse effects caused by systemic administration. The potential anatomical link between the non-invasive nose–brain pathway and the lesion site of depression may provide a more attractive option for the delivery of antidepressant active ingredients. The purpose of this article is to describe the specific link between intranasal administration and depression, the challenges of intranasal administration, as well as studies of intranasal administration of antidepressant active ingredients.
format Online
Article
Text
id pubmed-9611373
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96113732022-10-28 Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients Jin, Zhiyu Han, Yu Zhang, Danshen Li, Zhongqiu Jing, Yongshuai Hu, Beibei Sun, Shiguo Pharmaceutics Review As a mental disease in modern society, depression shows an increasing occurrence, with low cure rate and high recurrence rate. It has become the most disabling disease in the world. At present, the treatment of depression is mainly based on drug therapy combined with psychological therapy, physical therapy, and other adjuvant therapy methods. Antidepressants are primarily administered peripherally (oral and intravenous) and have a slow onset of action. Antidepressant active ingredients, such as neuropeptides, natural active ingredients, and some chemical agents, are limited by factors such as the blood–brain barrier (BBB), first-pass metabolism, and extensive adverse effects caused by systemic administration. The potential anatomical link between the non-invasive nose–brain pathway and the lesion site of depression may provide a more attractive option for the delivery of antidepressant active ingredients. The purpose of this article is to describe the specific link between intranasal administration and depression, the challenges of intranasal administration, as well as studies of intranasal administration of antidepressant active ingredients. MDPI 2022-09-28 /pmc/articles/PMC9611373/ /pubmed/36297505 http://dx.doi.org/10.3390/pharmaceutics14102070 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jin, Zhiyu
Han, Yu
Zhang, Danshen
Li, Zhongqiu
Jing, Yongshuai
Hu, Beibei
Sun, Shiguo
Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
title Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
title_full Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
title_fullStr Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
title_full_unstemmed Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
title_short Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
title_sort application of intranasal administration in the delivery of antidepressant active ingredients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611373/
https://www.ncbi.nlm.nih.gov/pubmed/36297505
http://dx.doi.org/10.3390/pharmaceutics14102070
work_keys_str_mv AT jinzhiyu applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients
AT hanyu applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients
AT zhangdanshen applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients
AT lizhongqiu applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients
AT jingyongshuai applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients
AT hubeibei applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients
AT sunshiguo applicationofintranasaladministrationinthedeliveryofantidepressantactiveingredients